Drug Profile
ORG 27306
Latest Information Update: 22 Jan 2010
Price :
$50
*
At a glance
- Originator Organon
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 19 Nov 2007 Organon has been acquired by Schering-Plough
- 01 Dec 2006 Phase-I clinical trials in Thrombosis in USA (unspecified route)